Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. / Davidsen, B; Munkholm, P; Schlichting, P; Nielsen, O H; Krarup, H; Bonnevie-Nielsen, V.
I: Alimentary Pharmacology and Therapeutics, Bind 9, Nr. 1, 02.1995, s. 75-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease
AU - Davidsen, B
AU - Munkholm, P
AU - Schlichting, P
AU - Nielsen, O H
AU - Krarup, H
AU - Bonnevie-Nielsen, V
PY - 1995/2
Y1 - 1995/2
N2 - BACKGROUND AND AIMS: Due to the need for new principles for the treatment of Crohn's disease and due to the documented immunomodulatory effects of interferon alpha, the tolerability and effect(s) of interferon alpha-2b (Introna) in active Crohn's disease were examined in a pilot study.METHODS: Five patients with active Crohn's disease (activity index (CDAI) scores of 235-517), were treated with interferon alpha-2b for 12 weeks.RESULTS: All patients tolerated the treatment, but developed influenza-like symptoms, which were fully controlled by paracetamol. Two patients obtained partial remission with a decline in activity index scores of 39% and 50%. The activity of 2',5'-oligoadenylate synthetase, which together with two other interferon-induced proteins, neopterin and beta 2-microglobulin were increased during treatment, indicated clearly an in vivo uptake of interferon. Sedimentation rate, C-reactive protein, orosomucoid, albumin, specific inflammatory markers: soluble interleukin-2 alpha-receptors (sIL-2R) and intercellular adhesion molecule-1 (ICAM-1) did not show any changes before or after treatment.CONCLUSION: Future multicentre investigations are required to evaluate the clinical effect of interferon alpha-2b treatment in active Crohn's disease.
AB - BACKGROUND AND AIMS: Due to the need for new principles for the treatment of Crohn's disease and due to the documented immunomodulatory effects of interferon alpha, the tolerability and effect(s) of interferon alpha-2b (Introna) in active Crohn's disease were examined in a pilot study.METHODS: Five patients with active Crohn's disease (activity index (CDAI) scores of 235-517), were treated with interferon alpha-2b for 12 weeks.RESULTS: All patients tolerated the treatment, but developed influenza-like symptoms, which were fully controlled by paracetamol. Two patients obtained partial remission with a decline in activity index scores of 39% and 50%. The activity of 2',5'-oligoadenylate synthetase, which together with two other interferon-induced proteins, neopterin and beta 2-microglobulin were increased during treatment, indicated clearly an in vivo uptake of interferon. Sedimentation rate, C-reactive protein, orosomucoid, albumin, specific inflammatory markers: soluble interleukin-2 alpha-receptors (sIL-2R) and intercellular adhesion molecule-1 (ICAM-1) did not show any changes before or after treatment.CONCLUSION: Future multicentre investigations are required to evaluate the clinical effect of interferon alpha-2b treatment in active Crohn's disease.
KW - 2',5'-Oligoadenylate Synthetase/blood
KW - Acetaminophen/administration & dosage
KW - Adult
KW - Biopterin/analogs & derivatives
KW - Blood Proteins/metabolism
KW - Crohn Disease/drug therapy
KW - Drug Evaluation
KW - Female
KW - Humans
KW - Influenza, Human/chemically induced
KW - Interferon alpha-2
KW - Interferon-alpha/adverse effects
KW - Male
KW - Middle Aged
KW - Neopterin
KW - Pilot Projects
KW - Recombinant Proteins
KW - beta 2-Microglobulin/metabolism
M3 - Journal article
C2 - 7766748
VL - 9
SP - 75
EP - 79
JO - Alimentary Pharmacology and Therapeutics, Supplement
JF - Alimentary Pharmacology and Therapeutics, Supplement
SN - 0953-0673
IS - 1
ER -
ID: 218727204